Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 14/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | FADS1 | O60427 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321772 | 0.77 | HSD11B1 (0.50) | HSD11B1ACHE | |
| SCHEMBL12350968 | 0.77 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL12350687 | 0.74 | HSD11B1 (0.46) | HSD11B1 | |
| SCHEMBL2360451 | 0.72 | KDM4E (0.43) | HSD11B1 | |
| SCHEMBL2319306 | 0.70 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL2322874 | 0.69 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL12350878 | 0.69 | SSTR4 (0.37) | HSD11B1 | |
| SCHEMBL2322132 | 0.68 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL13996487 | 0.68 | UTS2R (0.50) | ACHEMAPK10MAPK8ADRA2AFADS1 | |
| SCHEMBL2324160 | 0.67 | NPC1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011094953-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | claimed |
| WO-2011095576-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | claimed |
| WO-2011094953-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095576-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195979-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | NAT1, NHERF1, ADORA1 | HSD11B1 433/4885ACHE 856/4885MAPK10 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.